/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of.
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for.
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER - read this article along with other careers information, tips and advice on BioSpace